Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.
Garbe C. et al, (2012), Eur J Cancer, 48, 2375 - 2390
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012
Garbe C. et al, (2012), European Journal of Cancer, 48, 2375 - 2390
High-intensity focused ultrasound treatment of liver tumours: post-treatment MRI correlates well with intra-operative estimates of treatment volume.
Leslie T. et al, (2012), Br J Radiol, 85, 1363 - 1370
Sentinel node status predicts survival in thick melanomas: The Oxford perspective
Rughani MG. et al, (2012), European Journal of Surgical Oncology, 38, 936 - 942
Sentinel node status predicts survival in thick melanomas: the Oxford perspective.
Rughani MG. et al, (2012), Eur J Surg Oncol, 38, 936 - 942
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K. et al, (2012), Eur J Cancer, 48, 2175 - 2182
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
Johnston K. et al, (2012), European Journal of Cancer, 48, 2175 - 2182
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
Gillies RS. et al, (2012), Eur Radiol, 22, 2035 - 2043
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
Gillies RS. et al, (2012), European Radiology, 22, 2035 - 2043
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?
Hill EJ. et al, (2012), Crit Rev Oncol Hematol, 83, 353 - 387
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research?
Hill EJ. et al, (2012), Critical Reviews in Oncology/Hematology, 83, 353 - 387
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S. et al, (2012), Clin Cancer Res, 18, 4794 - 4805
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT. et al, (2012), N Engl J Med, 367, 107 - 114
Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review
Juszczak A. et al, (2012), European Journal of Endocrinology, 167, 1 - 5
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A. et al, (2012), Eur J Endocrinol, 167, 1 - 5
CLINICAL DIAGNOSTIC IMPLEMENTATION OF AN INNOVATIVE CANCER CARE MODEL BASED ON COMPREHENSIVE MOLECULAR PROFILING OF TUMOUR-NORMAL PAIRS
Kaur K. et al, (2012), ANNALS OF ONCOLOGY, 23, 12 - 13
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Cummings J. et al, (2012), Br J Cancer, 106, 1766 - 1771
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
Cummings J. et al, (2012), British Journal of Cancer, 106, 1766 - 1771
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Gupta A. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30